Cramer's Wild Card Jim Cramer's enthusiasm for BillionToOne is infectious, but does it warrant a buy recommendation?
The Mad Money host has a reputation for spotting gems, and his endorsement of the diagnostics company is likely to send shares soaring.
However, beneath the surface lies a more complex story – one that highlights the risks and rewards of investing in AI driven biotech firms.